Molecular diagnostics company Myriad Genetics, Inc. (MYGN) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved its BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza (olaparib).
from RTT - Biotech https://ift.tt/2LLDFVm
via IFTTT
No comments:
Post a Comment